menu
    • menu
    [{"orgOrder":0,"company":"AnaMar","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Covance"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAS 49715-04-0","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaMar \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"AnaMar \/ Covance"}]

    Find Clinical Drug Pipeline Developments & Deals by AnaMar

    Menu

    AnaMar

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AM1476

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Systemic Sclerosis

                            Details : AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist. It is being evaluated in phase 1 clinical trials for the treatment of Systemic Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : AM1476

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AM1476

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

                            Details : AM1476, as a pan anti-fibrotic medicine targeting 5-HT2B receptor and highly selective small molecule, delivered as an orally administered tablet.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : AM1476

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AM1476

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects

                            Details : AM1476 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 31, 2020

                            Lead Product(s) : AM1476

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            AnaMar

                            Sweden arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAS 49715-04-0

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

                            Details : AM1030 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 05, 2015

                            Lead Product(s) : CAS 49715-04-0

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.